The 11^th Edition of International Exhibition and Healthcare, is scheduled from September 4–6, 2025, at Bharat Mandapam, New Delhi. Organized by the Pharmexcil (Pharmaceuticals Export Promotion Council of India), with the support of Ministry of Commerce and Industry, this event will convene key stakeholders from the pharmaceutical industry and allied sectors.

The event will feature dedicated International Buyers Sellers Meet, a focused exhibition with over 700 stall with a strong emphasis on research & development and innovation. It will also spotlight India’s leading pharmaceutical exporters—across formulations, biosimilars, bulk drugs, and surgical—who are serving healthcare needs in over 150 countries.

Namit Joshi, Chairman of Pharmexcil, commented, “Now in its 11th edition, iPHEX has firmly established itself as a flagship global platform that showcases India’s pharmaceutical excellence. This year, the event expands its scope to include allied segments such as pharmaceutical machinery and Ayush products—broadening its relevance and impact. iPHEX has consistently created synergy and confidence among global pharma stakeholders, offering an exclusive environment for focused one-on-one business meetings, regulatory dialogues, and strategic partnerships. Our objective is to reinforce India’s position as the preferred global partner for high-quality, affordable pharmaceuticals.”

Vice Chairman of Pharmexcil, Bhavin Mehta also shared his perspective on the event, “iPHEX 2025 is a cornerstone in India’s pharmaceutical trade diplomacy, uniquely designed to go beyond a traditional exhibition. With participation from regulators and buyers across NAFTA, EU, Africa, ASEAN, CIS, LAC, and WANA regions, the event facilitates deep engagement through contract manufacturing discussions, technology transfers, and bilateral trade collaborations. As a niche, high-value platform, iPHEX continues to drive market access and position India as an innovation-led, reliable force in global pharma supply chains.”

K Raja Bhanu, Director General, Pharmexcil, shared,”The 11th Edition of IPHEX 2025 promises to be a pivotal event for the global pharmaceutical industry. It will bring together over 25,000 domestic visitors and 700+ pharma exhibitors, with delegates from 111+ countries. The USP of Indian Generics has always been 'Quality, affordability, and scalability.' This will continue to be foundational as we move towards 'Bharath @2030 and beyond envisioning for speciality generics, biosimilars, vaccines & biologics, personalised medicines, advanced gene therapies, and CDMO/CRO services with a market size of 150 billion USD by 2030. We will achieve this through bold and strategic investments, smart domestic and foreign trade policy initiatives, regulatory harmonisation and an ecosystem that fosters innovation and collaboration among stakeholders. By leveraging the ever-evolving strength of digital technology we will distinguish ourselves as a trusted and indispensable partner for global healthcare solutions.”